Abstract
The increase in organ demand for liver transplantation has exceeded the supply, resulting in longer waiting periods and higher death rates on the waiting list. As a consequence, most liver transplant centers throughout US and Europe have resorted to using suboptimal donors to expand the donor pool. The most recent papers have reported that the percentage of HCV(+) recipients who are transplanted with HCV(+) donors is more than 10 % of cases. In the near future, it is expected that a larger number of HCV(+) liver transplant candidates will be offered an HCV(+) graft. This means that greater experience on the management of both HCV infection and fibrosis progression will be requested from the transplant hepatologist. At the same time, since the rate of donation has reached a plateau since 2006, it is probable that older donors and grafts with mild-to-moderate steatosis will be used. There is growing evidence showing that the outcome of HCV(+) recipients is not different whether they receive an HCV(+) or an HCV(−) graft in terms of graft and patient survival. However, it is mandatory that liver biopsies of HCV(+) donors must show minimal or likely no fibrosis and minimal inflammation in order to be used for grafting. In this new scenario, the adequacy of the match between donor and recipient may be paramount since a decreased survival might be expected in high-risk patients receiving organs from suboptimal donors. In HCV(+) recipients from HCV(+) donors we should ensure an accepted graft and patient survival with no excessive costs for the transplant community. The benefit of liver transplantation should be evaluated in this subset of the population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fink MA, Berry SR, Gow PJ, Angus PW, Wang BZ, Muralidharan V, et al. Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol. 2007 Jan;22(1):119–24. Erratum in: J Gastroenterol Hepatol. 2007 Mar;22(3:457).
Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol. 2011 Mar;54(3):462–70.
Klein AS, Messersmith EE, Ratner LE, Kochik R, Baliga PK, Ojo AO. Organ donation and utilization in the United States, 1999–2008. Am J Transplant. 2010 Apr;10(4 Pt 2):973–86.
Neuberger J, Thomas G. When the law meets organ transplantation: the experience from the United kingdom. Transplantation. 2011 Aug 15;92(3):262–4.
Burra P, Freeman R. Trends in liver transplantation 2011. J Hepatol. 2012;56 (Suppl 1):S101–11.
Dutkowski P, De Rougemont O, Müllhaupt B, Clavien PA. Current and future trends in liver transplantation in Europe. Gastroenterology. 2010 Mar;138(3):802–9.
www.ont/es/publicaciones/documents/newsletter2011.pdf. Accessed 14 June 2012.
www.eurotransplant.org/cmc/index.php?page=onmail-reports. Accessed 14 June 2012.
Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011 Jun 15;91(11):1265–72.
Uemura T, Nikkel LE, Hollenbeak CS, Ramprasad V, Schaefer E, Kadry Z. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C? Transpl Int. 2012 Jun;25(6):671–9.
Lai JC, O’Leary JG, Trotter JF, Verna EC, Brown RS Jr, Stravitz RT, et al. Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012 May;18(5):532–8.
Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009 Jan 22;9:34.
Emiroglu N. Viral Hepatitis Burden and Policy Directions in the European Region of WHO. Keynote speech. WHO Regional Office for Europe Summit Conference on Hepatitis B and C. Brussels, October 14th, 2010.
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat. 2011 Sep;18 (Suppl 1):1–16.
www.who.int/immunization/topics/hepatitis_c/en/. Accessed 14 June 2012.
Burra P, Porte RJ. Should donors and recipients be matched in liver transplantation? J Hepatol. 2006 Oct;45(4):488–94.
Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008 Dec;14(12):1694–707.
Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, et al. Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. Am J Transplant. 2011 Dec;11(12):2724–36.
Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003 Sep;3(9):1167–72.
Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010 Oct;23(10):1038–44.
Burr AT, Li Y, Tseng JF, Saidi RF, Bozorgzadeh A, Shah SA. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011 Jul;35(7):1590–5.
Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant. 2009 Apr;9(4 Pt 2):970–81.
Aloia TA, Knight R, Gaber AO, Ghobrial RM, Goss JA. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors. Liver Transpl. 2010 Aug;16(8):950–9.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693–9.
Mukherjee S, Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology. 2008 May;134(6):1777–88.
Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl. 2006 Oct;12(10):1496–503.
Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009 Jun;15(6):619–28.
Avolio AW, Agnes S, Cillo U, Lirosi MC, Romagnoli R, Baccarani U, et al. http://www.D-MELD.com, the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. Transpl Int. 2012 Mar;25(3):294–301.
Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005 Jul–Aug;37(6):2569–70.
Hu A, Liang W, Zheng Z, Guo Z, He X. Living donor vs. deceased donor liver transplantation for patients with hepatitis C virus-related diseases. J Hepatol. 2012 Dec;57(6):1228–43.
Fan X, Lang DM, Xu Y, Lyra AC, Yusim K, Everhart JE, et al. Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strains. Hepatology. 2003 Jul;38(1):25–33.
Laskus T, Wang LF, Rakela J, Vargas H, Pinna AD, Tsamandas AC, Demetris AJ, Fung J. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology. 1996 Jun 1;220(1):171–6.
O’Leary JG, Neri MA, Trotter JF, Davis GL, Klintmalm GB. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int. 2012 Aug;25(8):825–9.
Ramirez S, Perez-del-Pulgar S, Carrion JA, Coto-Llerena M, Mensa L, Dragun J, et al. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. J Gen Virol. 2010;91:1183–9.
Bitetto D, Falleti E, Fornasiere E, Belli L, Viganò R, Fagiuoli S, et al. Interaction between cyclosporine and recipient IL-28B RS12979860 C > T genetic polymorphisms in the achievement of sustained viral response for recurrent Hepatitis C. J Hepatol. 2012(56):S2–S37.
Gastaca M. Extended criteria donors in liver transplantation: adapting donor quality and recipient. Transplant Proc. 2009 Apr;41(3):975–9.
Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008 May;134(6):1699–714.
Merion RM, Sharma P, Mathur AK, Schaubel DE. Evidence-based development of liver allocation: a review. Transpl Int. 2011 Oct;24(10):965–72.
Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):659–68.
Testa G, Goldstein RM, Netto G, Abbasoglu O, Brooks BK, Levy MF, Husberg BS, Gonwa TA, Klintmalm GB. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation. 1998 Apr 15;65(7):925–9.
Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, Fung JJ, Rakela J. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999 Jul;117(1):149–53.
Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, Edwards E, Taranto S, Johnson LB. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001 Sep;7(9):762–8.
Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, Zeldin G, Stewart C, Blumberg E, Abrams J, Markmann JF. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002 Feb 27;73(4):582–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Burra, P., Fagiuoli, S. (2014). Use of Anti-HCV Positive Grafts in Liver Transplantation. In: Berenguer, M. (eds) Hepatitis C Virus and Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8438-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8438-7_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8437-0
Online ISBN: 978-1-4614-8438-7
eBook Packages: MedicineMedicine (R0)